Validation and refinement of survival models for liver retransplantation

Hugo R. Rosen, Martin Prieto, Teresa Casanovas-Taltavull, Valentin Cuervas-Mons, Olaf Guckelberger, Paolo Muiesan, Russell W. Strong, Wolf O. Bechstein, John O'Grady, Atif Zaman, Benjamin Chan, Joaquin Berenguer, Roger Williams, Nigel Heaton, Peter Neuhaus

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P <.0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P = .004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model X2 = 105, P <.0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.

Original languageEnglish (US)
Pages (from-to)460-469
Number of pages10
JournalHepatology
Volume38
Issue number2
DOIs
StatePublished - Aug 1 2003

Fingerprint

Survival
Liver
End Stage Liver Disease
International Normalized Ratio
Prothrombin Time
Bilirubin
ROC Curve
Registries
Creatinine
Survival Rate
Transplants
Mortality
Serum

ASJC Scopus subject areas

  • Hepatology

Cite this

Rosen, H. R., Prieto, M., Casanovas-Taltavull, T., Cuervas-Mons, V., Guckelberger, O., Muiesan, P., ... Neuhaus, P. (2003). Validation and refinement of survival models for liver retransplantation. Hepatology, 38(2), 460-469. https://doi.org/10.1053/jhep.2003.50328

Validation and refinement of survival models for liver retransplantation. / Rosen, Hugo R.; Prieto, Martin; Casanovas-Taltavull, Teresa; Cuervas-Mons, Valentin; Guckelberger, Olaf; Muiesan, Paolo; Strong, Russell W.; Bechstein, Wolf O.; O'Grady, John; Zaman, Atif; Chan, Benjamin; Berenguer, Joaquin; Williams, Roger; Heaton, Nigel; Neuhaus, Peter.

In: Hepatology, Vol. 38, No. 2, 01.08.2003, p. 460-469.

Research output: Contribution to journalArticle

Rosen, HR, Prieto, M, Casanovas-Taltavull, T, Cuervas-Mons, V, Guckelberger, O, Muiesan, P, Strong, RW, Bechstein, WO, O'Grady, J, Zaman, A, Chan, B, Berenguer, J, Williams, R, Heaton, N & Neuhaus, P 2003, 'Validation and refinement of survival models for liver retransplantation', Hepatology, vol. 38, no. 2, pp. 460-469. https://doi.org/10.1053/jhep.2003.50328
Rosen HR, Prieto M, Casanovas-Taltavull T, Cuervas-Mons V, Guckelberger O, Muiesan P et al. Validation and refinement of survival models for liver retransplantation. Hepatology. 2003 Aug 1;38(2):460-469. https://doi.org/10.1053/jhep.2003.50328
Rosen, Hugo R. ; Prieto, Martin ; Casanovas-Taltavull, Teresa ; Cuervas-Mons, Valentin ; Guckelberger, Olaf ; Muiesan, Paolo ; Strong, Russell W. ; Bechstein, Wolf O. ; O'Grady, John ; Zaman, Atif ; Chan, Benjamin ; Berenguer, Joaquin ; Williams, Roger ; Heaton, Nigel ; Neuhaus, Peter. / Validation and refinement of survival models for liver retransplantation. In: Hepatology. 2003 ; Vol. 38, No. 2. pp. 460-469.
@article{bb190d7a1c8e44cd8f728214a41b4e2d,
title = "Validation and refinement of survival models for liver retransplantation",
abstract = "Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72{\%}, 68{\%}, and 36{\%}, respectively (P <.0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P = .004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model X2 = 105, P <.0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.",
author = "Rosen, {Hugo R.} and Martin Prieto and Teresa Casanovas-Taltavull and Valentin Cuervas-Mons and Olaf Guckelberger and Paolo Muiesan and Strong, {Russell W.} and Bechstein, {Wolf O.} and John O'Grady and Atif Zaman and Benjamin Chan and Joaquin Berenguer and Roger Williams and Nigel Heaton and Peter Neuhaus",
year = "2003",
month = "8",
day = "1",
doi = "10.1053/jhep.2003.50328",
language = "English (US)",
volume = "38",
pages = "460--469",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Validation and refinement of survival models for liver retransplantation

AU - Rosen, Hugo R.

AU - Prieto, Martin

AU - Casanovas-Taltavull, Teresa

AU - Cuervas-Mons, Valentin

AU - Guckelberger, Olaf

AU - Muiesan, Paolo

AU - Strong, Russell W.

AU - Bechstein, Wolf O.

AU - O'Grady, John

AU - Zaman, Atif

AU - Chan, Benjamin

AU - Berenguer, Joaquin

AU - Williams, Roger

AU - Heaton, Nigel

AU - Neuhaus, Peter

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P <.0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P = .004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model X2 = 105, P <.0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.

AB - Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P <.0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P = .004). Utilizing both patient cohorts (n = 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model X2 = 105, P <.0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0042766826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042766826&partnerID=8YFLogxK

U2 - 10.1053/jhep.2003.50328

DO - 10.1053/jhep.2003.50328

M3 - Article

VL - 38

SP - 460

EP - 469

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -